Business
Patients dosed in VLP Peanut PROTECT trial
Patients dosed in VLP Peanut PROTECT trial.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n \n (\"Allergy Therapeutics\", \"ATL\" or the \"Group\")\n \n \n \n \n \n \n \n \n Allergy Therapeutics announces dosing of patients has commenced in Phase I PROTECT trial investigating novel peanut allergy vaccine candidate, VLP Peanut\n \n \n \n \n \n \n \n \n \n 27 March 2023\n \n Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first application of VLP Peanut in peanut allergic patients has commenced with the Group's innovative, short-course peanut allergy vaccine candidate in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy.\n \n \n \n \n \n Allergy Therapeutics' wholly-owned, subcutaneous, recombinant vaccine candidate incorporates novel virus-like particle (VLP) technology, which enhances the body's immune response by making the peanut allergen resemble an inactive virus.\n \n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.\n \n \n \n \n \n \n \n \n \n - ENDS -\n \n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n Allergy Therapeutics\n \n \n \n +44 (0) 1903 845 820\n \n \n Manuel Llobet, Chief Executive Officer\n \n \n Martin Hopcroft, Interim Chief Financial Officer\n \n \n \n \n \n \n Panmure Gordon (Nominated Adviser and Broker)\n \n \n \n +44 (0) 20 7886 2500\n \n \n Freddy Crossley, Emma Earl, Corporate Finance\n \n \n Rupert Dearden, Corporate Broking\n \n \n \n \n \n \n Consilium Strategic Communications\n \n \n \n +44 20 3709 5700\n \n \n Mary-Jane Elliott / David Daley / Davide Salvi\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes for editors:\n \n \n \n \n \n \n \n \n \n About Allergy Therapeutics\n \n \n \n \n \n \n \n \n Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed ...